2Nilsson B,Bümming P,Meis-Kindblom JM,et al.Gastrointestinal stromal tumors:the incidence,prevalence,clinical course,and prognostication in the preimatinib mesylate era-a population-based study in western Sweden[J].Cancer,2005,103(4):821-829.
4Blay JY,Bonvalot S,Casali P,et al.Consensus meeting for the management of gastrointestinal stromal tumors.Report of the GIST Consensus Conference of 20-21 March 2004,under the auspices of ESMO[J].Ann Oncol,2005,16(4):566-578.
5Demetri GD,Benjamin R,Blanke CE,et al.NCCN Task Force report:optimal management of patients with gastrointestinal stromal tumors(GIST)-expansion and update of NCCN clinical practice guideline[J].J Natl Compr Cancr Netw,2004,2(suppl 1):s1-s26.
6DeMatteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival[J].Ann Surg,2000,231(1):51-58.
3Von Mehren M. New therapeutic strategies for soft tissue sarcomas.Curr Treat Options Oncol,2003 ,4 :441-451.
4Bauer S, Yu LK, Demetri GD, et al. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res ,2006, 66:9153-9161.
5Kawai J, Kodera Y, Fujiwara M, et al. Telomerase activity as prognostic factor in gastrointestinal stromal tumors of the stomach. Hepategastro- enterology, 2005,52 : 959 -964.
6Kimura S, Maekawa T, Hirakawa K, et al. Alterations of c-myc expres- sion by antisense oligoxynucleotides enhance the induction of apoptosis in HL 260 cells. Cancer Res, 1995,55 : 1379-1384.
